CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Rhea-AI Summary
CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on neurological conditions, has successfully closed its upsized initial public offering (IPO). The company sold 12,196,969 shares of common stock at $17.00 per share, including 1,590,909 additional shares from the full exercise of the underwriters' option. The IPO raised approximately $207.3 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.
CeriBell's common stock began trading on the Nasdaq Global Select Market on October 11, 2024, under the ticker symbol CBLL. BofA Securities and J.P. Morgan served as joint book-running managers and representatives of the underwriters, with William Blair, TD Cowen, and Canaccord Genuity acting as co-managers for the offering.
Positive
- Successful closing of upsized IPO, raising approximately $207.3 million in gross proceeds
- Full exercise of underwriters' option to purchase additional shares, indicating strong demand
- Listing on the Nasdaq Global Select Market, potentially increasing visibility and liquidity
Negative
- Potential dilution of existing shareholders due to the issuance of new shares
News Market Reaction – CBLL
In the trading session that priced this news, CBLL gained 3.53%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BofA Securities and J.P. Morgan acted as joint book-running managers and as representatives of the underwriters for the offering. William Blair, TD Cowen and Canaccord Genuity acted as co-managers for the offering.
A registration statement relating to the shares sold in this offering was filed with the Securities and Exchange Commission and became effective on October 10, 2024. The offering was made only by means of a prospectus, copies of which may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ceribell
Ceribell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Ceribell System is an AI-powered, rapidly deployable point-of-care electroencephalography ("EEG") platform designed to address the unmet needs of patients in the acute care setting. The company is headquartered in
INVESTOR CONTACT
Brian Johnston or Laine Morgan
Gilmartin Group, LLC
investors@ceribell.com
MEDIA CONTACT
Corrie Rose
Press@ceribell.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ceribell-inc-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-302277031.html
SOURCE Ceribell, Inc.